Vicatertidepeptide The dominant search intent for "sb01 peptide" is to understand what this synthetic peptide is, its composition, its mechanism of action, and its clinical development, particularly concerning its potential to treat chronic low back pain caused by degenerative disc disease.
Core Entities & High-Relevance Phrases (Tier 1):
* sb01 peptide
* synthetic 7-amino acid peptide
* Vicatertide (also known as SB-01)
* Transforming Growth Factor Beta 1 (TGF-β1)
* antagonizes TGF-β activity/inhibitor
* chronic low back pain
* degenerative disc disease (DDD)
* SB-01 For Injection
Supporting Entities & Concepts (Tier 2):
* Spine BioPharma
* down-regulation of TGF-β1
* pleiotropic cytokine
* intradiscal pharmacologic treatment
* pain-related function
* orthopaedic sports medicine
* peripheral nerve injury
* Remedisc
Weaker/Repetitive/Potentially Noisy Terms (Tier 3):
* SBP1 peptide (different peptide)
* SB01 - StabilBlot™ Protein-Free Blocker (unrelated product)
* YH14618 (appears to be a research code for SB-01)
* "SB-01 peptide for sale," "Sb 01 peptide reddit" (commercial/forum-based, not core scientific info)
---
The sb01 peptide, known scientifically as Vicatertide, is a synthetic 7-amino acid peptide developed to target inflammation associated with certain medical conditions2024年9月24日—SB-01 is a 7-amino acid synthetic peptidethat binds to and antagonizes TGF-Beta activity. TGF-Beta is a pleiotropic cytokine expressed by .... Its primary focus in clinical development has been as a potential treatment for chronic low back pain stemming from degenerative disc disease (DDD).Learn about SB-01 - SpineBioPharma By acting as an inhibitor, SB-01 aims to modulate the activity of Transforming Growth Factor Beta 1 (TGF-β1), a cytokine implicated in inflammatory processes that contribute to DDD.SB-01 Injection for Degenerative Disc Disease (MODEL Trial)
SB-01 is a precisely engineered molecule composed of seven amino acids2024年7月10日—SB-01 is a 7-amino acid synthetic peptidethat binds to and antagonizes TGF-Beta. TGF-Beta is a pleiotropic cytokine expressed by almost every .... Its development is spearheaded by Spine BioPharma, where it is also referred to by the investigational name Vicatertide or RemediscYH14618 (SB-01; P2K). The peptide's core function is to antagonize TGF-β activity. TGF-β is a crucial cytokine found throughout the body, playing various roles in cell growth, differentiation, and immune response.2024年9月25日—SB-01 is claimed to be the first intradiscal pharmacologic treatmentto enter Phase III trials for CLBP management and associated functional ... However, its dysregulation can lead to excessive inflammation and tissue remodeling, which are hallmarks of degenerative conditions like DDDSpine BioPharma Completes Enrollment for SB-01 Phase .... SB-01 is designed to counteract these detrimental effects by binding to and inhibiting TGF-β signaling pathways.
Transforming Growth Factor Beta 1 (TGF-β1) is a pleiotropic cytokine that, when overexpressed or dysregulated, can promote fibrosis and inflammation. In the context of degenerative disc disease, elevated levels of TGF-β1 are believed to contribute to the breakdown of the disc matrix and the onset of chronic pain. SB-01 functions by binding to TGF-β1, thereby blocking its interaction with cellular receptors and preventing the downstream signaling cascades that drive inflammation and tissue degradationVicatertide is a TGF beta-1 inhibitor. For research use only. We do not sell to patients. Custom Peptide Synthesis. Vicatertide Chemical .... This targeted approach aims to halt or reverse the degenerative process at its source.
The most significant application of the SB-01 peptide has been in clinical trials for degenerative disc disease (DDD), specifically for chronic low back pain and associated functional disability. Spine BioPharma has conducted extensive research, including Phase 3 clinical studies, to confirm the safety and effectiveness of SB-01 For InjectionLearn about SB-01 - SpineBioPharma. This formulation is designed for direct administration into the spinal disc, allowing for localized therapeutic action.
The peptide is being evaluated as a potential first-in-class intradiscal pharmacologic treatment for DDD. Clinical trial results have explored various endpoints, including pain intensity, pain-related function, and overall disability.SBP1 peptide While some trial phases have reported mixed results regarding primary endpoints, secondary analyses have often shown promising trends in pain reduction and improved function, suggesting a potential benefit for a subset of patients. The administration route as an injection into the spinal disc distinguishes SB-01 from systemic treatments, aiming for a more direct impact on the affected tissue while minimizing systemic side effects.
Beyond its primary investigation for DDD, the mechanism of SB-01's action suggests potential applications in other conditions where TGF-β dysregulation plays a role. Research into orthopaedic sports medicine and the repair of injuries, such as peripheral nerve injuries, sometimes involves peptides that modulate similar pathways.2022年9月7日—SB-01 is a 7-amino acid peptidethat binds to and antagonizes TGFβ1 activity. TGFβ1 is an inflammatory cytokine which is often highly ... While SB-01's development is heavily concentrated on its use in DDD, the broader understanding of TGF-β inhibition opens avenues for future exploration.
The journey of SB-01 peptide, or Vicatertide, highlights the ongoing effort to develop targeted therapies for chronic pain conditions. Its specific design as a 7-amino acid synthetic peptide targeting TGF-β1 positions it as an innovative approach to managing the complex pathology of degenerative disc disease. Continued analysis of clinical data and potential future research will further define its role in therapeutic interventions.
Join the newsletter to receive news, updates, new products and freebies in your inbox.